🔗 Visit the ClinicalTrials.gov page for NCT02468661
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. | Expert Rev Mol Diagn | 2016 | 0.80 |
| 2 | Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. | Front Oncol | 2016 | 0.79 |
| 3 | Liquid biopsy in the practice of neo-oncology. | J Thorac Dis | 2016 | 0.75 |